A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

NCT01833494 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemodialysis Patients With Hyperphosphatemia

Interventions

DRUG: PA21

Sponsor

Kissei Pharmaceutical Co., Ltd.